Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024
29 May 2024 - 10:00PM
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the
Company), a fully-integrated biopharmaceutical company with
marketed products and a pipeline of development candidates, today
announced two oral presentations and a poster presentation at the
American Transplant Congress 2024, being held June 1-5, 2024 at the
Pennsylvania Convention Center, Philadelphia, Pa. Details on each
presentation can be found below.
Copies of the Company’s poster presentations
will be available under the Scientific Presentations tab of the
Tonix website at www.tonixpharma.com following the conference.
Additional meeting information can be found on the American
Transplant Congress website here.
Oral
Presentations Details |
Presenter: |
|
Kohei Kinoshita, M.D., Center for Transplantation Sciences,
Massachusetts General Hospital |
Title: |
|
Combined Blockade of the CD154
and CD28 Co-Stimulation Pathways Attenuates Pathogenic Alloimmunity
and Prolongs Survival in Cynomolgus Cardiac Allografts |
Location: |
|
109-AB‚ Level 1 |
Abstract: |
|
860 |
Date/Time: |
|
Tuesday, June 4, 2024, 9:45
a.m. ET |
|
|
|
Presenter: |
|
Ikechukwu Ileka, M.D.,
Massachusetts General Hospital and Harvard Medical School |
Title: |
|
Extended Survival of 9- and
10-Gene-Edited Pig Heart Xenografts with Ischemia Minimization and
CD154 Costimulation Blockade-Based Immunosuppression |
Location: |
|
114 - Nutter Theater‚ Level
1 |
Abstract: |
|
932 |
Date/Time: |
|
Tuesday, June 4, 2024, 10:15
a.m. ET |
|
|
|
Poster
Presentations Details |
Presenter: |
|
Ikechukwu Ileka, M.D.,
Massachusetts General Hospital and Harvard Medical School |
Title: |
|
Experience with a Novel
Delayed Immune Tolerance Protocol in Nonhuman Primates Based on
Anti-CD154, Anti-CD2, and Anti-CD28 |
Location: |
|
Poster Hall‚ Exhibit Hall A‚
Level 2 |
Abstract: |
|
C086 |
Date/Time: |
|
Monday, June 3, 2024, 9:15
a.m. ET |
|
|
|
Tonix Pharmaceuticals Holding
Corp.*
Tonix is a fully-integrated biopharmaceutical
company focused on developing, licensing and commercializing
therapeutics to treat and prevent human disease and alleviate
suffering. Tonix’s development portfolio is focused on central
nervous system (CNS) disorders. Tonix’s priority is to submit a New
Drug Application (NDA) to the FDA in the second half of 2024 for
Tonmya1, a product candidate for which two statistically
significant Phase 3 studies have been completed for the management
of fibromyalgia. TNX-102 SL is also being developed to treat acute
stress reaction as well as fibromyalgia-type Long COVID. Tonix’s
CNS portfolio includes TNX-1300 (cocaine esterase), a biologic
designed to treat cocaine intoxication that has Breakthrough
Therapy designation. Tonix’s immunology development portfolio
consists of biologics to address organ transplant rejection,
autoimmunity and cancer, including TNX-1500, which is a humanized
monoclonal antibody targeting CD40-ligand (CD40L or CD154) being
developed for the prevention of allograft rejection and for the
treatment of autoimmune diseases. Tonix also has product candidates
in development in the areas of rare disease and infectious disease.
Tonix Medicines, our commercial subsidiary, markets Zembrace®
SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan
nasal spray) 10 mg for the treatment of acute migraine with or
without aura in adults.
*Tonix’s product development candidates are
investigational new drugs or biologics and have not been approved
for any indication.
1Tonmya™ is conditionally accepted by the U.S.
Food and Drug Administration (FDA) as the tradename for TNX-102 SL
for the management of fibromyalgia. Tonmya has not been approved
for any indication.
Zembrace SymTouch and Tosymra are registered
trademarks of Tonix Medicines. All other marks are property of
their respective owners.
This press release and further information about
Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as “anticipate,”
“believe,” “forecast,” “estimate,” “expect,” and “intend,” among
others. These forward-looking statements are based on Tonix's
current expectations and actual results could differ materially.
There are a number of factors that could cause actual events to
differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to, risks
related to the failure to obtain FDA clearances or approvals and
noncompliance with FDA regulations; risks related to the failure to
successfully market any of our products; risks related to the
timing and progress of clinical development of our product
candidates; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and substantial
competition. As with any pharmaceutical under development, there
are significant risks in the development, regulatory approval and
commercialization of new products. Tonix does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in the Annual
Report on Form 10-K for the year ended December 31, 2023, as filed
with the Securities and Exchange Commission (the “SEC”) on April 1,
2024, and periodic reports filed with the SEC on or after the date
thereof. All of Tonix's forward-looking statements are expressly
qualified by all such risk factors and other cautionary statements.
The information set forth herein speaks only as of the date
thereof.
Investor Contact
Jessica MorrisTonix
Pharmaceuticalsinvestor.relations@tonixpharma.com (862)
904-8182
Peter VozzoICR Westwickepeter.vozzo@westwicke.com (443)
213-0505
Media Contact
Katie
DodgeLaVoieHealthSciencekdodge@lavoiehealthscience.com(978)
360-3151
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From May 2024 to Jun 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Jun 2023 to Jun 2024